Category: Calcium-Activated Potassium (KCa) Channels

No significant hyperglycemia or QT interval prolongation was noted

No significant hyperglycemia or QT interval prolongation was noted. inhibitor linsitinib in individuals with advanced malignancy refractory to standard therapy. Methods. Dose escalation in three specified dose levels was performed relating to a standard 3?+?3 design. Dose levels were as follows: (a) linsitinib 400 mg and irinotecan 100 mg/m2, (b) linsitinib 450 mg and irinotecan […]